{"title":"Dissecting burden of alcoholic cardiomyopathy: age-period-cohort analysis from the global burden of disease study 2019.","authors":"Huatao Zhou, Yu Mao, Zilong Zheng, Zhi Tu, Yichen Li, Jinfu Yang, Wangping Chen, Chengming Fan","doi":"10.1080/10641963.2026.2636171","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Alcoholic cardiomyopathy (ACM) is a major cause of cardiovascular morbidity and mortality, characterized by ventricular dilation and impaired contractility resulting from chronic heavy alcohol use. Understanding its temporal and demographic trends is vital for guiding targeted public health interventions.</p><p><strong>Methods and findings: </strong>Using the Global Burden of Disease (GBD) 2019 dataset, we analyzed ACM trends from 1990 to 2019 across 204 countries and territories. Multi-level mixed-effects models were applied to assess age, period, and cohort effects on ACM mortality. Males consistently exhibited higher ACM rates across all age groups. Although global age-standardized prevalence and mortality rates have declined since 1990, regional disparities persist-mortality remains highest in Eastern Europe and lowest in Sub-Saharan Africa. Age, period, and cohort analyses revealed patterns reflecting cumulative alcohol-related cardiac damage, healthcare advancements, and generational shifts in alcohol consumption.</p><p><strong>Conclusions: </strong>Despite global improvement, ACM continues to impose a substantial health burden. Early interventions and policies addressing alcohol use throughout the life course are essential. Future longitudinal studies should identify critical prevention windows and explore genetic and environmental interactions. Advances in precision medicine, big data, and artificial intelligence may further enhance personalized treatment and optimize global resource allocation against ACM.</p>","PeriodicalId":10333,"journal":{"name":"Clinical and Experimental Hypertension","volume":"48 1","pages":"2636171"},"PeriodicalIF":6.8000,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10641963.2026.2636171","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Alcoholic cardiomyopathy (ACM) is a major cause of cardiovascular morbidity and mortality, characterized by ventricular dilation and impaired contractility resulting from chronic heavy alcohol use. Understanding its temporal and demographic trends is vital for guiding targeted public health interventions.
Methods and findings: Using the Global Burden of Disease (GBD) 2019 dataset, we analyzed ACM trends from 1990 to 2019 across 204 countries and territories. Multi-level mixed-effects models were applied to assess age, period, and cohort effects on ACM mortality. Males consistently exhibited higher ACM rates across all age groups. Although global age-standardized prevalence and mortality rates have declined since 1990, regional disparities persist-mortality remains highest in Eastern Europe and lowest in Sub-Saharan Africa. Age, period, and cohort analyses revealed patterns reflecting cumulative alcohol-related cardiac damage, healthcare advancements, and generational shifts in alcohol consumption.
Conclusions: Despite global improvement, ACM continues to impose a substantial health burden. Early interventions and policies addressing alcohol use throughout the life course are essential. Future longitudinal studies should identify critical prevention windows and explore genetic and environmental interactions. Advances in precision medicine, big data, and artificial intelligence may further enhance personalized treatment and optimize global resource allocation against ACM.
期刊介绍:
Clinical and Experimental Hypertension is a reputable journal that has converted to a full Open Access format starting from Volume 45 in 2023. While previous volumes are still accessible through a Pay to Read model, the journal now provides free and open access to its content. It serves as an international platform for the exchange of up-to-date scientific and clinical information concerning both human and animal hypertension. The journal publishes a wide range of articles, including full research papers, solicited and unsolicited reviews, and commentaries. Through these publications, the journal aims to enhance current understanding and support the timely detection, management, control, and prevention of hypertension-related conditions.
One notable aspect of Clinical and Experimental Hypertension is its coverage of special issues that focus on the proceedings of symposia dedicated to hypertension research. This feature allows researchers and clinicians to delve deeper into the latest advancements in this field.
The journal is abstracted and indexed in several renowned databases, including Pharmacoeconomics and Outcomes News (Online), Reactions Weekly (Online), CABI, EBSCOhost, Elsevier BV, International Atomic Energy Agency, and the National Library of Medicine, among others. These affiliations ensure that the journal's content receives broad visibility and facilitates its discoverability by professionals and researchers in related disciplines.